AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jun 03, 2014

AbbVie to Present at Jefferies 2014 Global Healthcare Conference

NORTH CHICAGO, Ill., June 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time.

Jun 03, 2014

AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland

-- €85 million investment creates greater manufacturing capacity to deliver new medicines for patients

May 31, 2014

AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of 84 percent, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States. These results were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30June 3 in Chicago.

May 30, 2014

AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology's 50th Annual Meeting

NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme. Specifically, one patient experienced a complete response (CR) and three patients experienced partial responses (PR) as measured with the Revised Assessment in Neuro-Oncology (RANO) criteria. These results were presented for the first time at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30June 3 in Chicago.

May 20, 2014

AbbVie to Present at 2014 UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time.

May 20, 2014

AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical program is in Phase III development. HUMIRA is not currently approved to treat any form of uveitis.

May 15, 2014

AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement

NORTH CHICAGO, Ill., May 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer.  Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline.

May 13, 2014

AbbVie to Present at Bank of America Merrill Lynch 2014 Health Care Conference

NORTH CHICAGO, Ill., May 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10 a.m. Central time.

May 08, 2014

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date[1]

Apr 25, 2014

AbbVie Reports First-Quarter 2014 Financial Results

NORTH CHICAGO, Ill., April 25, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2014.